Medical and Pharma Insider’s Post

#NCEMinus1Opportunity #alert Watch this video for more information about the NCE minus one opportunity for the molecule #Truqap to treat breast cancer that meets certain disease criteria. If you want to know more about this NCE minus 1 opportunity or want to conduct comprehensive research on the potential of this opportunity, write to us at bd@springbiosolution.com Visit us at https://lnkd.in/dw2U7yCr to learn more about us and our team. Check all the NCE minus 1 videos from 2023 here: https://lnkd.in/gF3Z3Yf5 Salim Shaikh Sadiq I Nikhila Shashikanth I Vrishali Sekhar I Pramila Coutinho I Vikrant Chudasama I Priyanka Kochrekar I Falak khan I Priyanka Ganeriwal I Shreyas Shendge I Akhilesh Chaudhari I Anuja Pandit | Ingrid Hoyos #SpringBioSolution #SpringBio #NCEMinus1 #NCEMinus1Opportunity #drugdiscovery #drugdevelopment #drugresearch #rlddrugs #genericmedicines #genericdrugs #clinicaltrials #pharma #pharmaindustry #pharmainnovation

📰 Great news for iOnctura today 📰 The FDA has granted permission to proceed with clinical investigations of roginolisib in the US! 👏   Roginolisib is in development for solid and hematologic malignancies including #uvealmelanoma and is the first allosteric modulator of #PI3Kδ. This marks a new era in #drugdevelopment within the class. Roginolisib has shown promising #clinical activity across patients with both solid and hematological cancers.   Read the press release linked below to find out more about roginolisib and its progress in the DIONE-01 trial, a two-part, first-in-human Phase I study. 👉  https://lnkd.in/eWXydRyP   #biotech #cancer

𝐅𝐃𝐀 𝐀𝐜𝐜𝐞𝐩𝐭𝐬 𝐏𝐌𝐀 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐍𝐨𝐯𝐨𝐜𝐮𝐫𝐞'𝐬 𝐓𝐓𝐅𝐢𝐞𝐥𝐝𝐬 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐢𝐧 𝐍𝐒𝐂𝐋𝐂 The FDA has officially accepted Novocure's Novocure Premarket Approval (PMA) application for the use of Tumor Treating Fields (TTFields) therapy alongside standard systemic therapies in non-small cell lung cancer (NSCLC). This application follows progression on or after platinum-based therapy. Asaf Danziger Asaf Danziger, Novocure’s Chief Executive Officer, stated, “The FDA's acceptance of our PMA application for NSCLC is a significant milestone. We appreciate the efforts of our investigators, patients, and colleagues.” 📅 Key Dates: PMA Application Submission: December 15, 2023 Expected FDA Decision: Second half of 2024 Stay tuned for further developments on this regulatory process. #FDAApproval #NSCLC #MedicalInnovation #Healthcare #LUNARStudy #CancerTherapy #lungcancer

💜Today marks #RareDiseaseDay, shedding light on the challenges faced by those with uncommon conditions. "Rare cancers remain also rarely studied, and that's why we cannot stop working towards finding more options for the patients." says kishor Bhatia, Lantern Pharma Inc. (Nasdaq: LTRN)'s Chief scientific officer. Lantern Pharma is dedicated to pioneering solutions for patients with rare cancers, starting with our drug candidate, LP-184 and LP-284. Discover how Lantern pharma is leveraging AI for rare cancer treatments at www.lanternpharma.com. #RareCancerAwareness #AdvocacyMatters

Welcome to the team, Jon! CellCentric continuing to build leadership and expertise, as we scale up production of inobrodib, advancing to towards pivotal clinical studies. https://lnkd.in/eGGvsUei Inobrodib: first-in-class oral inhibitor of the bromodomain of p300/CBP. Treating specific cancers, notably multiple myeloma. #multiplemyeloma

#NCEMinus1Opportunity #alert Watch this video for more information about the NCE minus one opportunity for the molecule #Truqap to treat breast cancer that meets certain disease criteria. If you want to know more about this NCE minus 1 opportunity or want to conduct comprehensive research on the potential of this opportunity, write to us at bd@springbiosolution.com Visit us at https://lnkd.in/dw2U7yCr to learn more about us and our team. Check all the NCE minus 1 videos from 2023 here: https://lnkd.in/gF3Z3Yf5 Nikhila Shashikanth I Vrishali Sekhar I Pramila Coutinho I Vikrant Chudasama I Priyanka Kochrekar I Falak khan I Priyanka Ganeriwal I Shreyas Shendge I Akhilesh Chaudhari I Anuja Pandit | Ingrid Hoyos #SpringBioSolution #SpringBio #NCEMinus1 #NCEMinus1Opportunity #drugdiscovery #drugdevelopment #drugresearch #rlddrugs #genericmedicines #genericdrugs #clinicaltrials #pharma #pharmaindustry #pharmainnovation

The surge in cancer instances highlights the crucial role radiotheranostics plays in transforming global healthcare.   Per The Business Research Company’s Radiotheranostics Global Market Report 2023, Cancer Research UK reported 18 million new cancer cases, with projections foreseeing a staggering 54.9% increase by 2040, reaching 28 million cases annually.   Understand how radiotheranostics medicines stand at the forefront, offering the promise of personalized treatment through diagnostic and therapeutic radionuclide probes.   Explore our comprehensive report for an in-depth analysis radiotheranostics market: https://lnkd.in/dJP5P3Vu . . . #radiotheranostics #radiopharmaceuticals #targetedradiotreatmen #cancerresearch #tbrc #thebusinessresearchcompany #marketresearch #marketintelligence

Theralase Technologies (TSXV: TLT) CEO Roger DuMoulin-White joined Steve Darling from Proactive to share details of an update on the company's Phase II Non-Muscle Invasive #BladderCancer clinical study during an interview with Steve Darling from Proactive. DuMoulin-White shared the significant findings from the study, revealing that it has provided the primary study treatment to 63 patients. The interim clinical data from Study II shows promising results, with a Complete Response (CR) rate of 54% at 6 months, 38% at 12 months, and 37% at 15 months. These CR rates surpass the guidelines set by the International Bladder Cancer Group (IBCG). Additionally, at the 90 Day Assessment Visit, 56% of Evaluable Patients achieved a CR, and 63% achieved a Total Response (CR + IR). At 450 days, 37% achieved a CR, and 41% achieved a TR. Watch at #Proactive #ProactiveInvestors #TSXV #OTCQB #TLT #TLTFF http://ow.ly/YLin10598yw

📢 Excited to share our new study w/Genentech on how #offlabel drugs are used in 165K #cancer patients https://lnkd.in/gsgaeSrk Takeaways👇: *19% of patients receive off-label cancer drugs (4% for off-guideline); tend to be younger or at academic sites *we IDed mutations predicting treatment outcome *immunotherapies often used before FDA approval *we also built a #transformer to predict when patients receive off-guideline treatments. Much more in our paper! #realworldevidence #cancertreatment #machinelearning Fantastic job by Ruishan Liu, Lisa Wang, Shemra Rizzo, Navdeep Pal, Marius Garmhausen, Sarah Waliany, Sarah McGough, PhD, Yvonne Lin, Zhi Huang, Joel Neal and Ryan Copping 👏👏

Discover the hurdles in Rare Cancer Drug Development 🧬 with ERGOMED whitepaper titled "Identifying the Challenges in Rare Cancers Drug Development." Did you know? 🔍 1 in 5 cancers is considered rare 🔍 The incidence for rare cancers is less than 6 individuals per 100,000 a year 🔍 There are estimated to be 200 rare cancers Learn about the unique challenges researchers face with rare cancers by downloading our whitepaper here: https://lnkd.in/duXGekKm For personalized guidance and solutions tailored to your needs, contact Ergomed's expert team! #RareDiseaseAwareness #RareCancers #ResearchMatters